Article Text

Download PDFPDF
EP883 Repeated use of maintenance therapy olaparib in patients with platinum-sensitive relapse of ovarian cancer
  1. S Khokhlova
  1. Chemotherapy Department, National Medical Research Center of Gynecology and Obstetrics n.a, V. I. Kulakov, Ministry of Health, Moscow, Russian Federation


Introduction/Background Experience of repeated use of maintenance therapy olaparib in patients with platinum-sensitive relapse of ovarian cancer in patients with a BRCA1 or BRCA2 (BRCA1/2) mutation.

Methodology In pilot trial evaluated olaparib capsules maintenance retreatment in platinum-sensitive, relapsed ovarian cancer patients with a BRCA1/2 mutation who had received at least four lines of previous platinum -containing chemotherapy and one maintenance line of olaparib therapy. The primary endpoint was progression-free survival the first maintenance therapy of olaparib and then reappointment of olaparib in maintenance therapy.

Results Between Sept 2014, and May 2019, 21 patients received maintenance olaparib for at least 3 lines of previous platinum-containing chemotherapy lines with a median survival without progression for 17,2 months (6–38 months). Among 21 patients 10 patients have progressed (6–29 months) and they were renewed with platinum-containing chemotherapy (gemcitabine with cisplatin (6 pts), doxorubicin with cisplatin (2 pts), paclitaxel with carboplatin (2 pts). The complete response was observed in 2 patients and in 8- partial. All 10 patients were restarted olaparib maintenance therapy. Median survival without progression of repeated maintenance treatment was 9,4 months (4–14 months). Two patients reapplication olaparib was longer than at the first use. When repeated administration of olaparib toxicity of 3 or worse severity was not observed. Toxicity of grade 1 or 2 was fatigue or asthenia (8 of 10 pts), anaemia (2 of 10 pts). At the first use of olaparib as a maintenance treatment, grade 3 anemia was observed in 2 from 21 patients, nausea grade 2 in 11 from 21 patients, fatigue and asthenia grade 2 in 17 from 21 patients.

Conclusion Olaparib maintenance retreatment provided a significant progression-free survival improvement with no detrimental effect on the quality of life in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation. With repeated use of olaparib, toxicity was less pronounced.

Disclosure Nothing to disclose.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.